RESUMEN
BACKGROUND: Atopic dermatitis (AD) is a chronic, inflammatory skin condition affecting up to one-quarter of children. Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep and development. The humanized monoclonal antibody nemolizumab, used concomitantly with topical agents, was shown to reduce pruritus and improve QoL in patients with AD aged ≥ 13â years. However, data relating to its efficacy and safety in younger children (aged < 13â years) have been lacking. OBJECTIVES: To evaluate the efficacy and safety of nemolizumab, administered concomitantly with topical agents, in Japanese paediatric patients (aged 6-12â years) with AD and inadequately controlled moderate-to-severe pruritus. METHODS: This was a randomized, placebo-controlled, double-blind, parallel-group, multicentre, 16-week, phase III study. Patients aged ≥ 6 and < 13â years, with confirmed AD, and an inadequate pruritic response despite treatment with topical agents and oral antihistamines were randomly assigned (1 : 1) to receive nemolizumab 30â mg or placebo every 4 weeks (Q4W). The primary efficacy endpoint was the change in the weekly mean 5-level itch score from baseline to week 16; secondary efficacy endpoints were related to pruritus, indicators for AD and QoL. Safety was assessed via adverse events (AEs) and laboratory test results. RESULTS: In total, 89 patients were enrolled, received either nemolizumab 30â mg (n = 45) or placebo (n = 44) Q4W, and completed the study. The mean patient age was 9.1 (SD 1.9) years, and mean duration of AD was 8.5 (2.7) years. The change in 5-level itch score from baseline to week 16 showed a statistically significant difference in the nemolizumab treatment group (-1.3) compared with placebo (-0.5; least-squares mean difference -0.8, 95% confidence interval -1.1 to -0.5; P < 0.0001). Improvements with nemolizumab were observed from the second day of administration. Secondary endpoints were in favour of nemolizumab. No AEs resulted in discontinuation, and the overall safety profile in patients aged 6-12â years was comparable with that in older patients (aged ≥ 13â years) with AD. CONCLUSIONS: Nemolizumab is a potential new treatment option for paediatric patients with AD whose pruritus has not been sufficiently improved with topical treatments and antihistamines.
Asunto(s)
Dermatitis Atópica , Humanos , Niño , Anciano , Dermatitis Atópica/complicaciones , Dermatitis Atópica/tratamiento farmacológico , Calidad de Vida , Inyecciones Subcutáneas , Prurito/etiología , Prurito/complicaciones , Antagonistas de los Receptores Histamínicos/uso terapéutico , Método Doble Ciego , Resultado del Tratamiento , Índice de Severidad de la EnfermedadRESUMEN
OBJECTIVE: Detailed quantitative studies on olfaction remain inadequate in patients with paediatric allergic rhinitis (AR). This study examined olfactory dysfunction in children with AR. METHODS: From July 2016 to November 2018, children aged 6-9 years were recruited and grouped as AR (n = 30) or without AR (control group, n = 10). Odour identification was evaluated by the Universal Sniff (U-Sniff) test and the Open Essence (OE). The results were compared between the AR and control groups. Intranasal mucosa findings, nasal smear eosinophil counts, blood eosinophil counts, total immunoglobulin E (IgE) levels, Japanese cedar-specific IgE and Dermatophagoides pteronyssinus-specific IgE were evaluated in all participants. Additionally, the presence of sinusitis and adenoid hypertrophy in patients with AR was also evaluated by sinus X-ray examinations. RESULTS: The median U-Sniff test scores were not significantly different between the AR and control groups (9.0 vs. 10.0, respectively; p = 0.107). The OE score was significantly lower in the AR group than in the control group (4.0 vs. 8.0; p = 0.007, respectively), especially in the moderate-to-severe AR group versus the control group (4.0 vs. 8.0; p = 0.004). Furthermore, in the OE, the correct answer rates for 'wood', 'cooking gas' and 'sweaty socks' were significantly lower in the AR group than in the control group. CONCLUSIONS: Paediatric AR patients can reduce olfactory identification ability, and the degree may be associated with the severity of AR in nasal mucosal findings. Furthermore, olfactory dysfunction may slow down the response to 'emergency situations', such as gas leak.
Asunto(s)
Trastornos del Olfato , Senos Paranasales , Rinitis Alérgica , Humanos , Niño , Olfato , Rinitis Alérgica/complicaciones , Inmunoglobulina ERESUMEN
This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, the description about three new drugs, namely, dupilumab, delgocitinib, and baricitinib, has been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
Asunto(s)
Dermatitis Atópica , Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/patología , Emolientes/uso terapéutico , Glucocorticoides , Humanos , Japón , Pomadas/uso terapéutico , Tacrolimus/uso terapéuticoRESUMEN
This is the English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, descriptions of three new drugs, namely, dupilumab, delgocitinib, and baricitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
Asunto(s)
Dermatitis Atópica , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/tratamiento farmacológico , Emolientes/uso terapéutico , Glucocorticoides/uso terapéutico , Humanos , Pomadas/uso terapéutico , Tacrolimus/uso terapéuticoRESUMEN
BACKGROUND: Cow's milk (CM) is an increasingly common cause of severe allergic reactions, but there is uncertainty with respect to severity of reactions at low-level CM exposure, as well as the reproducibility of reaction thresholds. OBJECTIVE: We undertook an individual participant data (IPD) meta-analysis of studies reporting double-blind, placebo-controlled food challenges in CM to determine the rate of anaphylaxis to low-level exposures and the reproducibility of reaction thresholds. METHODS: We performed a systematic review and IPD meta-analysis of studies reporting relevant data. Authors were contacted to provide additional data and/or clarification as needed. Risk of bias was assessed using the National Institute for Clinical Excellence methodologic checklists. RESULTS: Thirty-four studies were included, representing data from over 1000 participants. The cumulative ED01 and ED05 (cumulative doses causing objective symptoms in 1% and 5% of the at-risk allergic population) were 0.3 (95% confidence interval [CI], 0.2-0.5) and 2.9 (95% CI, 1.6-5.4) mg, respectively. At meta-analysis, 4.8% (95% CI, 2.0-10.9) and 4.8% (95% CI, 0.7-27.1) of individuals reacting to ≤5 mg and ≤0.5 mg of CM protein had anaphylaxis (minimal heterogeneity, I2 = 0%). Then 110 individuals underwent repeat double-blind, placebo-controlled food challenges; the intraindividual variation in reaction threshold was limited to a ½-log change in 80% (95% CI, 65-89) of participants. Two individuals initially tolerated 5 mg CM protein but then reacted to this dose at a subsequent challenge, although neither had anaphylaxis. CONCLUSIONS: About 5% of CM-allergic individuals reacting to ED01 or ED05 exposure might have anaphylaxis to that dose. This equates to 5 and 24 anaphylaxis events per 10,000 patients exposed to an ED01 or ED05 dose, respectively, in the broader CM-allergic population. Most of these anaphylactic reactions would be mild and respond to a single dose of epinephrine.
Asunto(s)
Anafilaxia , Hipersensibilidad a la Leche , Bovinos , Femenino , Animales , Humanos , Leche/efectos adversos , Hipersensibilidad a la Leche/complicaciones , Anafilaxia/etiología , Reproducibilidad de los Resultados , Alérgenos/efectos adversos , Proteínas , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Cough and sputum are common complaints at outpatient visits. In this digest version, we provide a general overview of these two symptoms and discuss the management of acute (up to three weeks) and prolonged/chronic cough (longer than three weeks). Flowcharts are provided, along with a step-by-step explanation of their diagnosis and management. Most cases of acute cough are due to an infection. In chronic respiratory illness, a cough could be a symptom of a respiratory infection such as pulmonary tuberculosis, malignancy such as a pulmonary tumor, asthma, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis, drug-induced lung injury, heart failure, nasal sinus disease, sinobronchial syndrome, eosinophilic sinusitis, cough variant asthma (CVA), atopic cough, chronic laryngeal allergy, gastroesophageal reflux (GER), and post-infectious cough. Antibiotics should not be prescribed for over-peak cough but can be considered for atypical infections. The exploration of a single/major cause is recommended for persistent/chronic cough. When sputum is present, a sputum smear/culture (general bacteria, mycobacteria), cytology, cell differentiation, chest computed tomography (CT), and sinus X-ray or CT should be performed. There are two types of rhinosinusitis. Conventional sinusitis and eosinophilic rhinosinusitis present primarily with neutrophilic inflammation and eosinophilic inflammation, respectively. The most common causes of dry cough include CVA, atopic cough/laryngeal allergy (chronic), GER, and post-infectious cough. In the last chapter, future challenges and perspectives are discussed. We hope that the clarification of the pathology of cough hypersensitivity syndrome will lead to further development of "pathology-specific non-specific therapeutic drugs" and provide benefits to patients with chronic refractory cough.
Asunto(s)
Tos/etiología , Tos/terapia , Guías de Práctica Clínica como Asunto , Neumología/organización & administración , Sociedades Médicas/organización & administración , Esputo , Enfermedad Aguda , Asma , Enfermedad Crónica , Tos/clasificación , Femenino , Reflujo Gastroesofágico , Humanos , Hipersensibilidad , Japón , Masculino , Enfermedades Respiratorias/complicaciones , Enfermedades Respiratorias/diagnóstico , Enfermedades Respiratorias/terapiaRESUMEN
BACKGROUND: Egg allergy is one of the most common food allergies in children. To date, oral immunotherapy (OIT) has been considered as a promising treatment option for egg allergy. However, safety issues remain concerning severe adverse events requiring epinephrine injection. Hence, establishing a safer method to treat egg allergy would be beneficial. We report here two children with egg allergy who were safely treated with sublingual immunotherapy (SLIT) before transitioning to OIT. CASE PRESENTATION: Patient 1 was a 7-year-old girl and Patient 2 was a 5-year-old girl. Although OIT for egg had been attempted in both patients, severe anaphylactic symptoms were induced by ingesting only 0.1 g of heated whole egg. Therefore, SLIT was conducted with aqueous suspensions consisting of water and heated whole egg powder. Suspensions were administered sublingually, kept in the mouth for 2 min, and spat out immediately thereafter. SLIT was continued for 7 months for Patient 1 and 8 months for Patient 2 due to the exploratory character of the study. Afterwards, the patients successfully transferred to low-dose OIT with 1 g of heated whole egg (â170 mg of egg protein) daily, and are continuing the therapy as of June 2020. As for adverse reactions, Patient 1 expressed oral cavity itchiness once at the beginning of SLIT. Patient 2 had no adverse reaction. The levels of antigen-specific IgE decreased in both patients after SLIT, and further decreased after switching to OIT. CONCLUSIONS: Few clinical studies have evaluated the efficacy and safety of SLIT for egg allergy. Although the treatment was conducted in only two patients, our results have shown that SLIT is a promising treatment procedure for egg allergy. Further clinical trials will be needed to additionally assess the efficacy and safety of SLIT in children with food allergy.
RESUMEN
BACKGROUND: This study was aimed at evaluating the efficacy and safety of oral immunotherapy (OIT) in children with severe cow's milk allergy. METHODS: The subjects comprised 28 children (aged 3-12 years) with allergic symptoms that were induced by ≤ 10 mL of cow's milk in an oral food challenge test (OFC). The subjects were randomly allocated to the treatment group (n = 14) and control group (n = 14); the former received rush immunotherapy for 2 weeks, followed by a gradual increase of cow's milk volume to 100 mL for 1 year, and the latter completely eliminated cow's milk for 1 year. Both groups underwent an OFC with 100 mL of cow's milk after 1 year. RESULTS: The treatment group had significantly higher rates of a negative OFC [7/14 (50%) vs. 0/14 (0%), p < 0.01] compared with the control group. The cow's milk-specific IgE level significantly decreased in the treatment group (p < 0.01) but not in the control group (p = 0.63). During the study period, adrenaline was required in 6/14 patients (43%) of the treatment group and in 0/14 patients (0%) of the control group. Long follow-up data were available at the 2-year point after the study for 8 in the treatment group and 7 (87.5%) of these continued to ingest milk (>100 mL). CONCLUSIONS: The effect of immunotherapy was 50%, but the incidence of adverse events was not low. Further studies focusing on safety is necessary to standardize OIT for cow's milk allergy.
Asunto(s)
Desensibilización Inmunológica , Hipersensibilidad a la Leche/terapia , Leche/efectos adversos , Administración Oral , Alérgenos/administración & dosificación , Alérgenos/efectos adversos , Animales , Niño , Preescolar , Desensibilización Inmunológica/efectos adversos , Método Doble Ciego , Femenino , Perfilación de la Expresión Génica , Humanos , Inmunoglobulina E/sangre , Japón , Leucocitos Mononucleares/inmunología , Masculino , Leche/inmunología , Hipersensibilidad a la Leche/sangre , Hipersensibilidad a la Leche/genética , Hipersensibilidad a la Leche/inmunologíaRESUMEN
BACKGROUND: The combination drug of inhaled corticosteroid (ICS)/long-acting ß2 agonist is being used as a long-term control medication for pediatric asthma patients for those who are poorly controlled by ICS alone. Long-term efficacy and safety of Fluticasone propionate/formoterol fumarate hydrate (FP/FM) was evaluated in pediatric patients with bronchial asthma. METHODS: Two inhales of FP/FM (50/5µg) at one time, twice daily were administered for 24 weeks to Japanese asthma patients aged 5 to ï¼16 years who had asthma symptoms during the observation period while using the same dosage of ICS during a certain period of time. Adverse drug reactions, morning peak flow (mPEF) and asthma symptoms were evaluated 24 weeks after administration. RESULTS: FP/FM was administered to 53 subjects. 52 subjects completed the 24 week administration. The incidence of adverse drug reactions was 9.4% (5 of 53), and all of the adverse drug reactions were mild. The mPEF increased from the starting value and was maintained through the treatment period. The average change from baseline in the mPEF after 24 weeks of treatment was 21.39±2.93L/min (Least squares mean±standard error). Changes in asthma symptoms were similar to that of morning peak flow. CONCLUSION: It was considered that FP/FM could be useful for long-term control of pediatric asthma.
Asunto(s)
Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Fluticasona/uso terapéutico , Fumarato de Formoterol/uso terapéutico , Administración por Inhalación , Adolescente , Corticoesteroides/uso terapéutico , Aerosoles/uso terapéutico , Broncodilatadores/efectos adversos , Niño , Preescolar , Combinación de Medicamentos , Fluticasona/efectos adversos , Fumarato de Formoterol/efectos adversos , Humanos , Japón , Resultado del TratamientoAsunto(s)
Bronquiolitis/diagnóstico , Bronquiolitis/tratamiento farmacológico , Infecciones por Haemophilus/diagnóstico , Infecciones por Haemophilus/tratamiento farmacológico , Adolescente , Asma/diagnóstico , Asma/tratamiento farmacológico , Niño , Femenino , Humanos , Pulmón/diagnóstico por imagen , Pulmón/patología , Macrólidos/uso terapéutico , Masculino , Resultado del TratamientoAsunto(s)
Alérgenos , Hipersensibilidad a los Alimentos , Escuelas de Párvulos , Lesiones Accidentales/tratamiento farmacológico , Lesiones Accidentales/epidemiología , Anafilaxia/tratamiento farmacológico , Anafilaxia/epidemiología , Preescolar , Epinefrina/administración & dosificación , Femenino , Hipersensibilidad a los Alimentos/tratamiento farmacológico , Hipersensibilidad a los Alimentos/epidemiología , Humanos , Incidencia , Lactante , Japón/epidemiología , Masculino , Encuestas y CuestionariosRESUMEN
BACKGROUND: Although the guidelines in most countries do not recommend continuous inhalation of l-isoproterenol to treat pediatric patients with acute severe exacerbation of asthma, lower dose of l-isoproterenol has been widely used in Japan. To determine whether the efficacy of low-dose l-isoproterenol was superior to that of salbutamol, we conducted a double-blind, randomized controlled trial. METHODS: Hospitalized patients aged 1-17 years were eligible if they had severe asthma exacerbation defined by the modified pulmonary index score (MPIS). Patients were randomly assigned (1:1) to receive inhalation of l-isoproterenol (10 µg/kg/h) or salbutamol (500 µg/kg/h) for 12 hours via a large-volume nebulizer with oxygen. The primary outcome was the change in MPIS from baseline to 3 hours after starting inhalation. Trial registration number UMIN000001991. RESULTS: From December 2009 to October 2013, 83 patients (42 in the l-isoproterenol group and 41 in the salbutamol group) were enrolled into the study. Of these, one patient in the l-isoproterenol group did not receive the study drug and was excluded from the analysis. Compared with salbutamol, l-isoproterenol reduced MPIS more rapidly. Mean (SD) changes in MPIS at 3 hours were -2.9 (2.5) in the l-isoproterenol group and -0.9 (2.3) in the salbutamol group (difference -2.0, 95% confidence interval -3.1 to -0.9; P < 0.001). Adverse events occurred in 1 (2%) and 11 (27%) patients in the l-isoproterenol and salbutamol groups, respectively (P = 0.003). Hypokalemia and tachycardia occurred only in the salbutamol group. CONCLUSIONS: Low-dose l-isoproterenol has a more rapid effect with fewer adverse events than salbutamol.
Asunto(s)
Albuterol/uso terapéutico , Asma/tratamiento farmacológico , Asma/fisiopatología , Broncodilatadores/uso terapéutico , Isoproterenol/uso terapéutico , Administración por Inhalación , Albuterol/administración & dosificación , Albuterol/efectos adversos , Broncodilatadores/administración & dosificación , Broncodilatadores/efectos adversos , Niño , Preescolar , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Lactante , Isoproterenol/administración & dosificación , Isoproterenol/efectos adversos , Pulmón/efectos de los fármacos , Pulmón/fisiopatología , Masculino , Resultado del TratamientoAsunto(s)
Antibacterianos/uso terapéutico , Asma/tratamiento farmacológico , Bronquitis/diagnóstico , Claritromicina/uso terapéutico , Sinusitis/diagnóstico , Antiasmáticos/uso terapéutico , Asma/complicaciones , Asma/diagnóstico , Bronquitis/complicaciones , Bronquitis/tratamiento farmacológico , Niño , Enfermedad Crónica , Diagnóstico Diferencial , Humanos , Masculino , Pruebas de Función Respiratoria , Sinusitis/complicaciones , Sinusitis/tratamiento farmacológico , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: There are no reports on the prevalence and social acceptance of food allergies (FAs) and FAinduced symptoms in nursery schools in Japan. PURPOSE: The purpose of this study is to clarify the current status of FA among children in nurseries. METHODS: Investigations were conducted in childcare facilities nationwide through survey request forms found on the Web page or sent via post. RESULT: We received responses from 15722 out of the 32210 institutions (48.8%) to whom survey request forms were sent.The overall prevalence of FA was 4.0%, with 6.4% at age less than 1 year, 7.1% at age 1, 5.1% at age 2, 3.6% at age 3, 2.8% at age 4, 2.3% at age 5, and 0.8% at age 6. Ninety-three point four percent of the institutions responded that they catered to children with FA, whereas 3.3% of the institutions responded that they did not. The details of the meal service were as follows: 52.4% were meals without causative foods, 39.5% were alternative meals without causative foods, and 3.3% were packed lunches from home. Seven point six percent of infants had at least one FA symptom in the institutions. CONCLUSION: Several nursery schools were accepting children with FA, and school lunches were also modified by removing causative food and providing alternative meals. On the other hand, several infants experience FA-induced symptoms, and it is necessary for each department to establish a system to reduce accidental ingestion and to ensure proper emergency response.
Asunto(s)
Guarderías Infantiles , Hipersensibilidad a los Alimentos , Responsabilidad Parental , Niño , Humanos , Lactante , Japón , Encuestas y CuestionariosRESUMEN
BACKGROUND: To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial. METHODS: Japanese patients aged 5-65 years were eligible for the study, if they had HDM-induced allergic rhinitis (AR), allergic bronchial asthma (BA), or both. TO-204 was administered in a dose titration scheme, and the maintenance dose was determined according to the predefined criteria. The treatment period was 52 weeks, and patients who were willing to continue the treatment received TO-204 beyond 52 weeks. This clinical trial is registered at the Japan Pharmaceutical Information Center (Japic CTI-121900). RESULTS: Between July 2012 and May 2015, 44 patients (28 with AR and 16 with allergic BA) were enrolled into the study. All patients were included in the analysis. The duration of treatment ranged from 23 to 142 weeks and the median maintenance dose was 200 Japanese allergy units (JAU). Adverse events occurred in 22 patients (50%). The most common adverse event was local reactions related to the injection sites. Four patients experienced anaphylactic reactions when they were treated with the dose of 500 JAU. Two patients experienced anaphylactic shock with the doses of 1000 JAU at onset. These 6 patients could continue the study with dose reduction. CONCLUSIONS: Safety profile of TO-204 was acceptable in Japanese patients with HDM-induced AR or allergic BA. Higher doses should be administered carefully, because the risk of anaphylaxis increased at doses of 500 or 1000 JAU.
Asunto(s)
Antígenos Dermatofagoides/administración & dosificación , Asma/terapia , Desensibilización Inmunológica/métodos , Rinitis Alérgica/terapia , Adolescente , Adulto , Anciano , Animales , Antígenos Dermatofagoides/efectos adversos , Pueblo Asiatico , Niño , Preescolar , Femenino , Humanos , Inyecciones Subcutáneas , Japón , Masculino , Persona de Mediana Edad , Pyroglyphidae/inmunología , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Periostin and squamous cell carcinoma antigen (SCCA) are involved in the pathogenesis of asthma. Acute bronchitis due to respiratory syncytial virus (RSV) infection during infancy exhibits an asthma-like pathogenesis, suggesting that it may be associated with the subsequent development of asthma. However, the mechanism by which RSV infection leads to development of asthma has not yet been fully elucidated. METHODS: Infants younger than 36 months were enrolled and classified into three groups. Group I included patients hospitalized with RSV-induced bronchitis. These patients were further stratified into two sub-groups according to whether the criteria for the modified Asthma Predictive Index (mAPI) had been met: Group I consisted of mAPI (+) and mAPI (-) patients; Group II included patients with food allergy as a positive control group; and Group III included children with no allergy as a negative control group. Serum periostin and SCCA levels were measured in the groups. This study was registered as a clinical trial (UMIN000012339). RESULTS: We enrolled 14 subjects in Group I mAPI (+), 22 in Group I mAPI (-), 18 in Group II, and 18 in Group III. In Group I, the serum periostin and SCCA levels were significantly higher during the acute phase compared with the recovery phase. However, no significant differences were found between Group I mAPI (+) and mAPI (-). CONCLUSIONS: The serum periostin and SCCA levels increased during acute RSV bronchitis. Both periostin and SCCA may play a role in the pathogenesis of acute bronchitis due to RSV.
Asunto(s)
Antígenos de Neoplasias/sangre , Bronquitis/sangre , Bronquitis/virología , Moléculas de Adhesión Celular/sangre , Infecciones por Virus Sincitial Respiratorio/sangre , Serpinas/sangre , Asma/sangre , Asma/virología , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Infecciones por Virus Sincitial Respiratorio/complicaciones , Regulación hacia ArribaRESUMEN
BACKGROUND: While Japanese guideline recommends initial control treatment for preschool children with asthma symptoms more than once a month, Western guidelines do not. To determine whether control treatment with montelukast was more effective than as-needed ß2-agonists in this population, we conducted a randomized controlled trial. METHODS: Eligible patients were children aged 1-5 years who had asthma symptoms more than once a month but less than once a week. Patients were randomly assigned in a 1:1 ratio to receive montelukast 4 mg daily for 48 weeks or as-needed ß2-agonists. The primary endpoint was the number of acute asthma exacerbations before starting step-up treatment with inhaled corticosteroids. This study is registered with the University Hospital Medical Information Network clinical trials registry, number UMIN000002219. RESULTS: From September 2009 to November 2012, 93 patients (47 in the montelukast group and 46 in the no-controller group) were enrolled into the study. All patients were included in the analysis. During the study, 13 patients (28%) in the montelukast group and 23 patients (50%) in the no-controller group had acute exacerbations with the mean numbers of 0.9 and 1.9/year, respectively (P = 0.027). In addition, 10 (21%) and 19 (41%) patients received step-up treatment, respectively. Cumulative incidence of step-up treatment was significantly lower in the montelukast group (hazard ratio 0.45, 95% confidence interval 0.21 to 0.92; P = 0.033). CONCLUSIONS: Montelukast is an effective control treatment for preschool children who had asthma symptoms more than once a month but less than once a week.
Asunto(s)
Acetatos/administración & dosificación , Agonistas de Receptores Adrenérgicos beta 2/administración & dosificación , Asma/tratamiento farmacológico , Quinolinas/administración & dosificación , Sistema de Registros , Acetatos/efectos adversos , Agonistas de Receptores Adrenérgicos beta 2/efectos adversos , Asma/epidemiología , Preescolar , Ciclopropanos , Femenino , Humanos , Lactante , Japón/epidemiología , Masculino , Quinolinas/efectos adversos , SulfurosAsunto(s)
Dermatitis Atópica , Hipersensibilidad a los Alimentos , Pediatría/educación , Anafilaxia , Asma , Niño , Humanos , Grupo de Atención al PacienteRESUMEN
BACKGROUND: Omalizumab is effective and well-tolerated in children with moderate to severe allergic asthma. However, the effects of long-term treatment with omalizumab in this population haven't been well investigated. The objective of this study is to evaluate the long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with uncontrolled severe asthma. METHODS: Thirty-eight Japanese children (aged 7-16 years) who completed the 24-week treatment core study were included in an uncontrolled extension study, in which treatment with omalizumab continued until the pediatric indication was approved in Japan (ClinicalTrials.gov number: NCT01328886). RESULTS: Thirty-five patients (92.1%) completed the extension study. The median exposure throughout the core and extension studies was 116.6 weeks (range, 46.9-151.1 weeks). The most common adverse events were nasopharyngitis, influenza, upper respiratory tract infection, and asthma. Serious adverse events developed in 10 patients (26.3%), but resolved completely with additional treatments. Incidence of adverse events didn't increase with extended exposure with omalizumab. Twenty-nine patients (76.3%) achieved completely- or well-controlled asthma compared with 9 patients (23.7%) at the start of the extension study. QOL scores, the rates (per year) of hospitalizations and ER visits were significantly improved compared with the baseline of the core study [39.0 vs 48.0 (median), p < 0.001 for QOL, 1.33 vs 0.16, p < 0.001 for hospitalization, 0.68 vs 0.15, p = 0.002 for ER visits]. Remarkably, the mean total IgE level showed a decreasing trend while exposure to omalizumab remained at steady-state. CONCLUSIONS: Long-term treatment with omalizumab is well-tolerated and effective in children with uncontrolled severe allergic asthma. No new safety findings were identified.